Satellos to Present New Clinical Data for SAT-3247 at ICNMD 2026
MSLE is trading near its 52-week low of $5.44 (3.3% above the low).
Summary
Satellos Bioscience announced it will present new six-month follow-up data from its Phase 1b SAT-3247 trial and updates on its Phase 2 TRAILHEAD study at the ICNMD 2026 conference in July.
Key Events · Product Development and Regulatory · MSLE
-
New Clinical Data Presentation Announced
Satellos Bioscience will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases (ICNMD) from July 7–11, 2026.
-
Phase 1b Follow-Up and Phase 2 Updates
The presentation will include six-month follow-up data from participants in the Phase 1b SAT-3247-CL-101 trial and updates from the ongoing Phase 2 TRAILHEAD (LT-001) trial for Duchenne muscular dystrophy.
-
Lead Candidate for Degenerative Muscle Diseases
SAT-3247 is an investigational oral small molecule drug candidate being developed for Duchenne muscular dystrophy and other degenerative muscle diseases, currently in Phase 2 studies (TRAILHEAD and BASECAMP).
Analysis · MSLE · Life Sciences
This filing announces that Satellos Bioscience will present new clinical data for its lead drug candidate, SAT-3247, at a major international conference in July. The presentation will include six-month follow-up data from a Phase 1b trial and updates on the ongoing Phase 2 TRAILHEAD study for Duchenne muscular dystrophy. For a clinical-stage biotech, these updates are critical for investor confidence and future development, especially as the company is trading near its 52-week low.
At the time of this filing, MSLE was trading at $5.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $117.1M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.